Good afternoon :)
$
₹
PDS Biotechnology Corp

PDS Biotechnology Corp

PDSB

NASDAQ
Asset Logo

PDS Biotechnology Corp

PDSB

NASDAQ
$1.224.27% (+0.05)
$
₹
$1.224.27% (+0.05)
High
—
—
Low
—
—
Returns
—
—
Loading...
1D
1W
1M
3M
6M
1Y
3Y
5Y
Max

Healthcare

Biotechnology

Micro Cap

With a market cap of $136.5M the stock is ranked 4504

Key Metrics

Key Metrics

PE TTM
PE TTM

Close price divided by the earnings per share for the trailing twelve months

—
PB
PB

Close price divided by the book value per share at the end of the most recent quarter

3.47
EPS TTM
EPS TTM

Net profit earned per share over the trailing twelve months (sum of the last 4 quarters)

$-0.59
PEG Ratio
PEG Ratio

Price-to-Earnings (P/E) ratio divided by the forecasted annual earnings per share (EPS) growth rate over the next five years

—
Profit Margin
Profit Margin

Net profit divided by the total revenue for the most recent financial year

0%
Dividend Yield
Dividend Yield

Annual dividend per share for the trailing twelve months divided by the close price

—

Analyst Ratings & Forecast

Analyst Ratings & Forecast

Detailed Forecast Detailed Forecast 

Based on 2 analysts reports

Buy
2 analysts
Hold
0 analyst
Sell
0 analyst

Price Upside

+265.85%

Earnings Growth

+42.67%

Rev. Growth

—

See Detailed Forecast

Company Profile

Company Profile

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101, a Versamune HPV, which is in phase II clinical trial for the treatment of head and neck, cervical, anal, vaginal, vulvar, and penile cancers. It also develops various product candidates, which are in preclinical trials, including PDS0102, an investigational immunotherapy utilizing tumor-associated and immunologically active T cell receptor gamma alternate reading framed protein for treating acute myeloid leukemia, prostate, and breast cancer; and PDS0103 for ovarian, breast, colorectal, and lung cancers. In addition, the company is developing PDS01ADC, a novel investigational Interleukin 12 fused antibody-drug conjugate, tumor-targeting interleukin 12 immune-cytokine that enhances the proliferation, potency, and longevity of T cells in the tumor microenvironment. It has a license and collaboration agreements with National Institutes of Health, Merck Eprova AG, The U.S. Department of Health and Human Services, Georgia Research Foundation, and MSD International GmbH. PDS Biotechnology Corporation was founded in 2005 and is based in Princeton, New Jersey.
PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101, a Versamune HPV, which is in phase II clinical trial for the treatment of head and neck, cervical, anal, vaginal, vulvar, and penile cancers. It also develops various product candidates, which are in preclinical trials, including PDS0102, an investigational immunotherapy utilizing tumor-associated and immunologically active T cell receptor gamma alternate reading framed protein for treating acute myeloid leukemia, prostate, and breast cancer; and PDS0103 for ovarian, breast, colorectal, and lung cancers. In addition, the company is developing PDS01ADC, a novel investigational Interleukin 12 fused antibody-drug conjugate, tumor-targeting interleukin 12 immune-cytokine that enhances the proliferation, potency, and longevity of T cells in the tumor microenvironment. It has a license and collaboration agreements with National Institutes of Health, Merck Eprova AG, The U.S. Department of Health and Human Services, Georgia Research Foundation, and MSD International GmbH. PDS Biotechnology Corporation was founded in 2005 and is based in Princeton, New Jersey.

Peers

Compare with peers Compare with peers 

Peers

Compare with peers Compare with peers 
AbbVie Inc
ABBV
AbbVie Inc
P/E Ratio
50.65
50.65
1Y Return
31.59%
31.59%
Buy Reco %
79.31
79.31
Amgen Inc
AMGN
Amgen Inc
P/E Ratio
27.73
27.73
1Y Return
46.88%
46.88%
Buy Reco %
35.29
35.29
Gilead Sciences Inc
GILD
Gilead Sciences Inc
P/E Ratio
—
—
1Y Return
35.24%
35.24%
Buy Reco %
78.57
78.57
Vertex Pharmaceuticals Inc
VRTX
Vertex Pharmaceuticals Inc
P/E Ratio
35.33
35.33
1Y Return
31.43%
31.43%
Buy Reco %
81.25
81.25
Moderna Inc
MRNA
Moderna Inc
P/E Ratio
—
—
1Y Return
944.75%
944.75%
Buy Reco %
17.39
17.39
Compare with Peers

Forecast

Forecast

Price

Revenue

Earnings

Price Forecast

Price Forecast

Higher price growth forecast versus trailing 3-year CAGR
Compares analyst forecast growth with historical annualized growth.

The 12-month consensus target implies 265.85% growth, versus a trailing 3-year CAGR of -35.90%.

2026
Current$1.23Baseline
Analyst Target - 1 year
Target$4.5+265.85%

All values in $

202220232024202520262027$4.15$7.61$11.06Target+265.85%
2026
Current$1.23Baseline
Analyst Target - 1 year
Target$4.5+265.85%

All values in $

Earnings Per Share Forecast

Earnings Per Share Forecast

2025
Current$-0.75Baseline
Forecast for Dec 2026
High$-0.37+50.67%
Average$-0.43+42.67%
Low$-0.49+34.67%

All values in $

202120222023202420252026-0.81-1.45-1.39-1.03-0.75Low+34.67%Average+42.67%High+50.67%
2025
Current$-0.75Baseline
Forecast for Dec 2026
High$-0.37+50.67%
Average$-0.43+42.67%
Low$-0.49+34.67%

All values in $

Financials

Financials

Income

Balance Sheet

Cash Flow

-9
-7.5
-7.3
-9.7
Q3 2025
Q4 2025
Q1 2026
Q2 2026
Revenue
Net Income
Financial YearQ1 2024Q2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026Q2 2026
Total Revenue0000.05000000
Net Income-10.60-8.32-10.72-7.95-8.48-9.43-9-7.56-7.34-9.75
Net Profit Margin----13463.50%------
See CostsAll values in $ Million

Peers

Peers & Comparison

Peers & Comparison

Comparing 2 stocks from
HealthcareBiotechnology

Valuation

Returns

Forecast

ScreenerCompare valuation on Screener
StockPE TTMPE TTMPBPBPEG RatioPEG Ratio
PDS Biotechnology Corp -3.47-
AbbVie Inc50.6550.450.58
Amgen Inc27.7321.332.75
ScreenerCompare valuation on Screener

Price Comparison

Price Comparison

Compare PDSB with any stock or ETF
Compare PDSB with any stock or ETF
Comparing from
PDSB
ABBV
AMGN
Loading...

Frequently asked questions

  1. PDS Biotechnology Corp (PDSB) share price today is $1.22 as of November 7, 2026 at 2:29 AM IST. The stock touched a day high of $1.26 and a day low of $1.17.

  2. PDS Biotechnology Corp stock trades on NASDAQ under the ticker symbol PDSB.

  3. PDS Biotechnology Corp's market capitalization is $136.5M as of November 7, 2026 at 2:29 AM IST.

  4. PDS Biotechnology Corp's price-to-earnings (P/E) ratio is N/A as of November 6, 2026.

  5. PDS Biotechnology Corp's price-to-book (P/B) ratio is 3.47 as of November 6, 2026.

  6. Yes, You can buy PDS Biotechnology Corp shares from India through Tickertape, via our partnership with ViewTrade IFSC under the IFSCA Global Access framework, subject to RBI’s Liberalised Remittance Scheme (LRS) limits.

  7. Indian investors can buy PDS Biotechnology Corp shares in three steps: 1. Search PDS Biotechnology Corp on the Tickertape app and tap Invest. 2. Complete your one-time digital KYC. 3. Fund your account and buy from as low as $1 via fractional shares.

  8. Since PDS Biotechnology Corp trades in USD, an Indian investor's INR returns depend on both the stock's price movement and the USD-INR exchange rate. If the rupee depreciates against the dollar, INR returns are boosted beyond the stock's USD return; if the rupee appreciates, INR returns are reduced.

  9. Indian investors can start investing in PDS Biotechnology Corp (PDSB) shares from as little as $1 through fractional ownership on Tickertape - for example, $10 buys approximately 8.1967 shares at the current price of $1.22.

Loading...